Eleflox, 500 mg 10 pcs

A broad spectrum antimicrobial agent. It has a pronounced bactericidal effect The drug inhibits both subunits of DNA-gyrase and topoisomerase IV, destroys the bacterial cell wall. It is also active against pneumococci and intracellular pathogens.

Owing to extremely high bioavailability and easy penetration inside the cell Eleflox reaches high concentrations in interstitial tissue fluid and inside cells.

The drug is usually administered once daily. 87% of Eleflox is excreted with urine in the active form, due to which high concentrations are achieved in the urogenital organs and prostate.

There is no need to adjust the dose if liver function is impaired. No change in dosing regimen is required for elderly patients, except in cases of low creatinine clearance.

Indications

Infectious and inflammatory diseases caused by sensitive microorganisms:

Respiratory tract infections (exacerbation of chronic bronchitis, community-acquired pneumonia)
Acute sinusitis
Urinary tract infections, uncomplicated and complicated: (pyelonephritis, cystitis, urethritis, etc.)
Prostatitis
Skin and soft tissue infections
Septicemia and bacteremia associated with the above indications
Intra-abdominal infection

Pharmacological effect

Broad-spectrum antimicrobial drug. Has a pronounced bactericidal effect. The drug inhibits both subunits of DNA gyrase and topoisomerase IV, destroys the bacterial cell wall. Also active against pneumococci and intracellular pathogens.

Due to its extremely high bioavailability and easy penetration into cells, Eleflox reaches high concentrations in the interstitial tissue fluid and inside cells.

The drug is usually prescribed once a day. 87% of Eleflox is excreted in the urine in active form, resulting in high concentrations in the genitourinary organs and prostate gland.

If liver function is impaired, no dose adjustment is required. For elderly patients, no change in dosage regimen is required, except in cases of low creatinine clearance.

Special instructions

Use levofloxacin with caution in elderly patients (high likelihood of concomitant decline in renal function).

After normalization of the temperature, it is recommended to continue treatment for at least 48-78 hours. The duration of intravenous infusion of 500 mg (100 ml of infusion solution) should be at least 60 minutes. During treatment, it is necessary to avoid solar and artificial UV irradiation to avoid damage to the skin (photosensitization). If signs of tendonitis appear, levofloxacin is immediately discontinued. It should be borne in mind that in patients with a history of brain damage (stroke, severe trauma), seizures may develop; with glucose-6-phosphate dehydrogenase deficiency, there is a risk of hemolysis.

Impact on the ability to drive vehicles and operate machinery

During the treatment period, it is necessary to refrain from engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Levofloxacin

Composition

Levofloxacin 500 mg.

Pregnancy

Levofloxacin is contraindicated for use during pregnancy and lactation (breastfeeding).

Contraindications

Hypersensitivity, epilepsy, tendon damage due to previous treatment with quinolones, pregnancy, lactation, children and adolescents under 18 years of age.

Side Effects

From the digestive system: nausea, vomiting, diarrhea, anorexia, abdominal pain, pseudomembranous enterocolitis, increased activity of liver transaminases, hyperbilirubinemia, hepatitis, dysbacteriosis.

From the cardiovascular system: decreased blood pressure, vascular collapse, tachycardia.

Metabolism: hypoglycemia (increased appetite, sweating, trembling).

From the central nervous system and peripheral nervous system: headache, dizziness, weakness, drowsiness, insomnia, paresthesia, anxiety, fear, hallucinations, confusion, depression, movement disorders, convulsions.

From the senses: disturbances of vision, hearing, smell, taste and tactile sensitivity.

From the musculoskeletal system: arthralgia, myalgia, tendon rupture, muscle weakness, tendonitis.

From the urinary system: hypercreatininemia, interstitial nephritis.

From the hematopoietic system: eosinophilia, hemolytic anemia, leukopenia, neutropenia, agranulocytosis, thrombocytopenia, pancytopenia, hemorrhages.

Dermatological reactions: photosensitivity, itching, swelling of the skin and mucous membranes, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome).

Allergic reactions: urticaria, bronchospasm, suffocation, anaphylactic shock, allergic pneumonitis, vasculitis.

Other: exacerbation of porphyria, rhabdomyolysis, persistent fever, development of superinfection.

Interaction

Levofloxacin increases T1/2 of cyclosporine.

The effect of levofloxacin is reduced by drugs that inhibit intestinal motility, sucralfate, magnesium- and aluminum-containing antacids and iron salts (a break of at least 2 hours is required between doses).

With simultaneous use of NSAIDs, theophylline increases convulsive readiness, corticosteroids increase the risk of tendon rupture.

Cimetidine and drugs that block tubular secretion slow down the elimination of levofloxacin.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Sun Pharmaceutical Industries Ltd, India